STATUS OF A---T POLYMORPHISM IN EXON II OF KINASE INSERT DOMAIN GENE IN WOMEN WITH PREMATURE OVARIAN FAILURE
Ovarian failure is defined as cessation of ovarian function under the age of 40 and it is characterized by amenorrhea hypo estrogenism and elevated gonadotrophin serum levels leading to infertility. Ovarian failure affects 1% of women. Causes of ovarian failure are extremely heterogenous. Ovarian failure is caused either by accelerated loss of eggs or the follicles themselves become less responsive to hormonal stimulation. It is high levels of gonadotrophins (luteinizing hormone and follicle stimulating hormone) hormonal defects may cause severe cardio vascular consequences and leads to the early onset of osteoporosis. Vascular endothelial growth factor (VEGF) is a major growth factor for endothelial cells. VEGF is involved in the process of angiogenesis for the development of Graffian follicle an important feature of growing follicle which has been arrested in the primordial follicular stage .VEGF mediates the process of angiogenesis through its receptors I and II.. Receptor II is known as Kinase insert domain receptor, is a type III receptor tyrosine Kinase.KDR is located at 4q11-q12.The main objective of this study was to screen the mutations in Kinase insert domain by using the techniques DNA isolation, Polymerase chain reaction and restriction fragment length polymorphism.
2. Risau W. Differentiation of endothelium, Faseb J. 1995; 9: 926–33.
3. Pepper MS. Positive and negative regulation of angiogenesis: From cell biology to the clinic, Vasc. Med.;1996.p. 259–66.
4. Kuiper RAJ, Schellens JHM, Blijham GH, Beijnen JH, Voest EE. Clinical research on antiangiogenic therapy. Pharma-col. Res. 1998; 37: 1–16.
5. Kumar R, Fidler IJ. Angiogenic molecules and cancer metastasis, In Vivo; 1998. p. 27–34.
6. Szekanecz Z, Szegedi G, Koch AE. Angiogenesis in rheumatoid arthritis: Pathogenic and clinical significance. J. Investig. Med. 1998; 46: 27–41.
7. Tolentino MJ, Adamis AP. Angiogenic factors in the development of diabetic iris neovascularization and retinopathy; Int. Ophthalmol. Clin. 1998; 38: 77–94.
8. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/ vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol. 1995; 146: 1029–39.
9. Thomas KA. Vascular endothelial growth factor, a potent and selective angiogenic agent; Cell. 1996; 271: 603–6.
10. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor Endocrine Rev.1997; 18: 4–25.
11. Borgström P, Hillan KJ, Sriranarao P, Ferrara N. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibodies. Novel concepts of angiostatic therapy from intravital videomicro-scopy. Cancer Res. 1996; 56: 4032–39.
12. Adamis AP, Miller JW, et al. Inhibition of VEGF prevents retinal ischemia-associated iris neovascularization in a primate; Arch. Ophthalmol. 1996;114:66–71.
13. Reproductive system , lorrie klosterman . .p. 5,6.
14. provided by RefSeq, NCBI Gene; 2009 May.
15. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocrine Rev. 1997; 18: 4–25.
16. Jeltsch M, Alitalo K, et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science. 1997; 276:1423–25.
17. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J. Biol. Chem. 1994; 269: 26988–95.
18. Seetharam L, Gotoh N, Maru Y, Neufeld G, Yamaguchi S, Shibuya M. A unique signal transduction pathway for the FLT tyrosine Kinase, a receptor for vascular endothelial growth factor, Oncogene. 1995; 10:135–47.
19. Shalaby F, Rossant J, Gertsenstein M, Wu XF, Breitman ML, Schuh AC. Failure of blood island formation and vasculogenesis in Flk-1 deficient mice. Nature. 1995; 376: 576–9
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The International Journal of Drug Regulatory affairs require a formal written transfer of copyright from the author(s) for each article published. We therefore ask you to complete and return this form, retaining a copy for your records. Your cooperation is essential and appreciated. Any delay will result in a delay in publication.
I/we have read and agree with the terms and conditions stated Page 2 of this agreement and I/we hereby confirm the transfer of all copyrights in and relating to the above-named manuscript, in all forms and media, now or hereafter known, to the International Journal of Drug Regulatory affairs, effective from the date stated below. I/we acknowledge that the IJDRA is relying on this agreement in publishing the above-named manuscript. However, this agreement will be null and void if the manuscript is not published in the IJDRA.
Download link for COPYRIGHT FORM